Sarepta released three‑year follow‑up data for its Duchenne gene therapy Elevidys, reporting durable benefits on motor function measures versus historical controls and an expanding gap between treated patients and external comparators. The company framed the results as evidence that therapeutic effects compound over time, a narrative aimed at reshaping commercial and clinical perception after a turbulent prior year marked by safety scrutiny and slowed sales. Wall Street analysts and clinicians acknowledged the data’s potential to bolster the efficacy case, but noted commercial impact hinges on whether safety concerns and labeling changes are resolved and whether results translate to renewed uptake. Clarification: Elevidys is an AAV‑based gene therapy intended to restore dystrophin expression in Duchenne muscular dystrophy.